Onxeo to Present New Preclinical Data at AACR 2021
Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]
B-Smart – Interview of Judith Greciet, CEO of Onxeo
Watch the interview (in French)
Onxeo will publish its annual results on April 21, 2021
The Annual General Meeting will be held on June 10, 2021 Paris (France), March 24, 2021 – 6 pm CET […]
ESMO Targeted Anticancer Therapies Congress 2021
Watch the e-poster “AsiDNA™ targets drug-tolerant persister cells responsible of resistance to PARP inhibitors”
4th Annual PARP & DDR Inhibitors Summit
For more information Download the presentation “AsiDNA™ and PARP inhibitors: Drug-driven synthetic lethality and beyond” Watch the video of […]
Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a phase 1b/2 Clinical Trial of AsiDNA™ in combination with radiotherapy for Treatment of High-Grade Glioma Relapse in Children
This study is supported by a grant from the European Fight Kids Cancer program[1] Paris (France), February 4, 2021 […]
Onxeo publishes Letter to Shareholders and provides update on its developments
Paris (France), February 2, 2021 – 9 pm CET – Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a […]
Onxeo Obtains Non-Dilutive Financing of 5 Million Euros in the Form of State Guaranteed Loans
This financing extends the Company’s cash horizon to the 3rd quarter of 2022 Paris (France), January 28, 2021 – […]
H.C. Wainwright Global Life Sciences Conference
For more information and to register …
Edison Open House Global Healthcare 2021
For more information, visit the Edison Open House Global Healthcare 2021 webpage Download the management presentation Access the interview […]
BioMed Event 2021
For more information, click here Download the management presentation
2020 – Full-year report on the liquidity contract
2020 Full-year report on the liquidity contract
Onxeo to Attend Key Investor and Scientific Conferences
Paris (France), January 11, 2021 – 7:00 am CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Onxeo Announces its Financial Agenda for 2021
Paris (France), January 7, 2021 – 6 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]